Model Introduction
KP-4 is a highly metastatic human pancreatic ductal adenocarcinoma (PDAC) cell line originally established from a liver metastatic lesion of a patient with advanced pancreatic cancer. This cell line is characterized by its aggressive invasive phenotype, strong metastatic capacity and high liver-tropism, closely recapitulating the disseminated and metastatic behavior of clinical pancreatic cancer. KP-4 cells express pancreatic ductal epithelial markers including CK19 and CA19-9, and exhibit a mesenchymal-like morphology consistent with epithelial-mesenchymal transition (EMT). The subcutaneous xenograft mouse model established with KP-4 cells is a valuable preclinical in vivo model for pancreatic cancer research, extensively applied in anti-tumor drug screening, anti-metastatic agent evaluation, targeted therapy research, nanoparticle delivery system validation and experimental metastasis studies. Different from less invasive PDAC cell lines, KP-4 is particularly suitable for investigating the metastatic cascade, liver colonization and therapeutic intervention against disseminated pancreatic cancer.
Experimental Principle
Immunodeficient BALB/c nude mice lack mature functional T lymphocytes and cannot mount effective cellular immune rejection against human-derived tumor xenografts. After harvesting KP-4 cells in logarithmic growth phase and preparing a single-cell suspension, the suspension is subcutaneously inoculated into the dorsal flank of recipient mice. Tumor cells progressively proliferate in subcutaneous tissue and recruit host stromal vasculature, forming solid tumor masses. Due to the inherent metastatic potential of KP-4, circulating tumor cells can disseminate via the bloodstream and colonize distant organs, particularly the liver. By regularly measuring tumor volume, body weight, metastatic burden and histopathological dissemination, researchers can quantitatively assess in vivo tumor growth kinetics, metastatic capacity and anti-tumor or anti-metastatic efficacy of test compounds.
Model Identification & Detection Indicators
- Tumor volume measurement: Starting from the day of visible tumor formation, the longest tumor diameter (L) and shortest diameter (W) are measured every 2–3 days using a vernier caliper. Tumor volume is calculated by the formula: TV (mm³) = 0.5 × L × W².
- Body weight monitoring: Body weight of each mouse is recorded synchronously with tumor volume measurement, serving as an indicator of systemic toxicity induced by tumor burden, cachexia or drug treatment. Progressive weight loss may also indicate metastatic disease.
- Model success criteria: The expected tumor formation rate of the KP-4 subcutaneous xenograft model is ≥90%. When tumor volume reaches 100–150 mm³ at approximately day 14–21 post inoculation, the model is considered successfully established and eligible for randomized grouping and therapeutic intervention.
- Primary tumor histopathological verification: At the experimental endpoint, primary tumor tissues are excised, fixed in 4% paraformaldehyde and embedded in paraffin. H&E staining confirms poorly differentiated ductal adenocarcinoma morphology. Immunohistochemistry detects biomarkers including CK19, vimentin, Ki-67 and CA19-9 to verify tumor origin, mesenchymal phenotype and proliferative activity.
- Metastasis evaluation: Liver, lung, spleen, peritoneum and regional lymph nodes are systematically harvested at necropsy. Visible metastatic nodules are counted and measured. H&E staining of organ sections confirms micrometastasis; human-specific Alu-qPCR can detect occult disseminated tumor cells in distant organs.
Model Advantages
- KP-4 is one of the few PDAC cell lines with documented spontaneous metastatic capacity, particularly liver tropism, making it a valuable tool for studying the metastatic cascade and anti-metastatic interventions.
- The model exhibits relatively fast primary tumor growth and near-complete take rate, with a short experimental cycle suitable for routine in vivo pharmacodynamic screening.
- KP-4 retains a mesenchymal, EMT-like phenotype, providing a biologically relevant model for investigating aggressive, disseminated pancreatic cancer.
- Subcutaneous inoculation allows convenient longitudinal measurement of primary tumor growth, while systematic necropsy enables comprehensive evaluation of spontaneous metastasis to distant organs.
Application Scenarios
- In vivo anti-tumor activity evaluation of small-molecule compounds, chemotherapeutic agents and targeted drugs against pancreatic cancer.
- Preclinical assessment of anti-metastatic agents, anti-EMT therapies and inhibitors of tumor microenvironment-mediated metastatic dissemination.
- Experimental metastasis research including liver colonization, circulating tumor cell biology and preclinical evaluation of anti-dissemination combination regimens.
- Mechanistic studies of pancreatic cancer invasion, epithelial-mesenchymal transition and metastatic organotropism, as well as nanoparticle or liposomal delivery system validation for metastatic pancreatic cancer.
Zvast Biotechnology
